Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SNOA 
Sonoma Pharmaceuticals Inc (SNOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: SNOA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.4
1 Year Target Price $13.4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.96% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.43M USD | Price to earnings Ratio - | 1Y Target Price 13.4 |
Price to earnings Ratio - | 1Y Target Price 13.4 | ||
Volume (30-day avg) 1 | Beta 1.62 | 52 Weeks Range 1.75 - 6.92 | Updated Date 01/9/2026 |
52 Weeks Range 1.75 - 6.92 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.54% | Operating Margin (TTM) -6.01% |
Management Effectiveness
Return on Assets (TTM) -14.16% | Return on Equity (TTM) -76.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3930067 | Price to Sales(TTM) 0.38 |
Enterprise Value 3930067 | Price to Sales(TTM) 0.38 | ||
Enterprise Value to Revenue 0.23 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 1701076 | Shares Floating 1680136 |
Shares Outstanding 1701076 | Shares Floating 1680136 | ||
Percent Insiders 1.19 | Percent Institutions 3.49 |
Upturn AI SWOT
Sonoma Pharmaceuticals Inc
Company Overview
History and Background
Sonoma Pharmaceuticals Inc. (formerly known as Oculex Pharmaceuticals) was founded in 1991. It has undergone several strategic shifts and name changes throughout its history, aiming to commercialize innovative technologies in the fields of ocular drug delivery and wound care. Key milestones include the development of its microinsert technology for sustained ocular drug delivery and its later pivot towards developing and commercializing antimicrobial and active wound care products based on its proprietary stabilized hypochlorous acid (HOCl) technology.
Core Business Areas
- Microinsert Technology (Historical): Developed and patented microinsert technology for sustained delivery of drugs to the eye, primarily for glaucoma treatment. This area has seen reduced focus in recent years.
- Antimicrobial and Wound Care Solutions: Focuses on the development, manufacturing, and commercialization of a broad range of advanced wound care and skin care products utilizing its proprietary stabilized hypochlorous acid (HOCl) technology. These products are used for treating wounds, skin infections, and other dermatological conditions.
Leadership and Structure
Sonoma Pharmaceuticals Inc. is led by a management team with expertise in pharmaceuticals, medical devices, and business development. The company operates with a lean organizational structure, focusing on research and development, manufacturing, and sales and marketing of its HOCl-based products. Specific leadership roles (CEO, CFO, etc.) can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- Product Name 1: DermAssistu00ae and Revizeku00ae (wound care): These are stabilized hypochlorous acid (HOCl) based solutions for cleansing, debriding, and irrigating wounds. They are marketed to healthcare professionals and consumers for various types of wounds, including chronic wounds, burns, and surgical sites. Competitors in this space include companies offering saline solutions, povidone-iodine solutions, and other antimicrobial wound care products. Market share data for specific products is not readily available publicly, but the overall advanced wound care market is substantial.
- Product Name 2: Microcynu00ae Technology: This is the underlying technology platform based on stabilized HOCl, used in a variety of medical, consumer, and veterinary applications. Products derived from this technology are used for infection control, skin care, and medical device disinfection. Competitors include manufacturers of other disinfectants, antiseptics, and antimicrobial agents. Specific market share for this technology platform is not publicly disclosed.
Market Dynamics
Industry Overview
Sonoma Pharmaceuticals operates in the global wound care and antimicrobial markets, which are driven by an aging population, increasing prevalence of chronic diseases (like diabetes), and advancements in medical technologies. The demand for effective and safe wound management solutions is growing, with a particular emphasis on products that promote healing and prevent infection. The antimicrobial resistance crisis also fuels the need for novel antimicrobial solutions.
Positioning
Sonoma Pharmaceuticals positions itself as a provider of innovative, science-backed antimicrobial and wound care solutions. Its competitive advantage lies in its proprietary stabilized hypochlorous acid (HOCl) technology, which is claimed to be effective against a broad spectrum of pathogens while being safe for human tissue. The company aims to differentiate itself through product efficacy, safety profile, and versatility of application.
Total Addressable Market (TAM)
The global wound care market is substantial and projected to continue growing, with estimates ranging from tens of billions of dollars annually. The antimicrobial market is also a multi-billion dollar global industry. Sonoma Pharmaceuticals, with its broad application of HOCl technology, aims to capture a share of these markets. Its positioning within this TAM is as a niche player with a proprietary technology seeking to disrupt traditional solutions in specific segments.
Upturn SWOT Analysis
Strengths
- Proprietary stabilized hypochlorous acid (HOCl) technology with broad-spectrum antimicrobial properties.
- Product portfolio for advanced wound care, skin care, and infection control.
- Established regulatory approvals and certifications for certain products.
- Potential for diverse applications across medical, consumer, and veterinary markets.
Weaknesses
- Limited brand recognition and market penetration compared to larger competitors.
- Dependence on third-party manufacturers for certain production aspects.
- Historical financial challenges and need for consistent revenue growth.
- Relatively small market share in a highly competitive landscape.
Opportunities
- Growing demand for advanced wound care solutions.
- Increasing awareness of antimicrobial resistance and need for new solutions.
- Expansion into new geographic markets and product applications.
- Potential strategic partnerships and collaborations.
- Development of new formulations and delivery systems for HOCl.
Threats
- Intense competition from established players and new entrants.
- Price sensitivity and reimbursement challenges in healthcare markets.
- Regulatory hurdles and changing healthcare policies.
- Emergence of alternative antimicrobial technologies.
- Economic downturns impacting healthcare spending.
Competitors and Market Share
Key Competitors
- 3M Company (MMM)
- Smith & Nephew (SNN)
- ConvaTec Group Inc. (CTVA)
Competitive Landscape
Sonoma Pharmaceuticals faces a highly competitive landscape with larger, more established companies in the wound care and antimicrobial sectors. Its advantage lies in its specialized HOCl technology, but it must overcome the significant market share, brand recognition, and distribution networks of its competitors. The company's success hinges on effectively differentiating its products and gaining traction in specific market niches.
Growth Trajectory and Initiatives
Historical Growth: Sonoma Pharmaceuticals has experienced periods of development and strategic shifts, with historical growth often tied to product development cycles and market adoption. Revenue growth has been a key focus, though often challenged by market penetration and competition.
Future Projections: Future growth projections are typically based on analyst estimates, which can vary. These projections would likely be linked to the expansion of its HOCl-based product lines, penetration into new markets, and successful commercialization of new applications.
Recent Initiatives: Recent initiatives have likely focused on expanding the commercialization of its wound care and skin care products, strengthening distribution channels, and potentially exploring new indications or partnerships for its HOCl technology.
Summary
Sonoma Pharmaceuticals Inc. possesses a promising proprietary technology in stabilized hypochlorous acid, offering potential in antimicrobial and wound care markets. Its strengths lie in its unique product formulation and diverse applications. However, the company faces significant challenges due to intense competition from established giants, limited market share, and the need for consistent financial performance. To thrive, Sonoma must effectively scale its commercialization efforts, expand its market penetration, and leverage its technological advantages to carve out a sustainable position in a dynamic industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Sonoma Pharmaceuticals Inc. Investor Relations website (SEC Filings)
- Financial news and market data providers (e.g., Yahoo Finance, Bloomberg)
- Industry research reports on wound care and antimicrobial markets
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Stock market investments are subject to risk. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data and TAM figures are estimates and subject to change. Historical financial performance does not guarantee future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonoma Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2007-01-25 | CEO, President & Director Ms. Amy M. Trombly Esq., J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8 | Website https://sonomapharma.com |
Full time employees 8 | Website https://sonomapharma.com | ||
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.